Wall Street’s Key Stock Analysts Research Report, All Buys

Wall Street’s Key Stock Analysts Research Report, All Buys

#buys #bullish #WallStreet #analysts

$CRSP $HIBB $SPT $TBIO $VIR

These are all Buys if you can manage the risk.

Daily HeffX-LTN reviews dozens of Wall Street’s Key analysts research reports to ID new trading and investing ideas for HeffX-LTN readers. These reports cover stocks to buy

Below is our list for Tuesday, 6 October, as follows:

CRISPR Therapeutics A.G. (NASDAQ:CRSP) was started with a Buy rating and a 110 price objective at BofA Securities. Shares have a 95.21 consensus price target.

Hibbett Sports Inc. (NASDAQ:HIBB): this retailer has produced some big beats and still has a very attractive valuation. Shares have a consensus price target of 39.50.

Sprout Social Inc. (NASDAQ:SPT) was reiterated as Buy and its price target was raised to 46 from 40 at Needham.

Translate Bio Inc. (NASDAQ:TBIO) was started with a Buy rating and a 19 price target at Goldman Sachs.

Vir Biotechnology Inc. (NASDAQ:VIR) was started with a Buy rating and its price objective was set at 55 at BofA Securities

Have a healthy day, Keep the Faith!

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, a polymath, excels, in diverse fields of knowledge Including Pattern Recognition Analysis in Equities, Commodities and Foreign Exchange, and he it the author of "The Red Roadmaster's Technical Report on the US Major Market Indices, a highly regarded, weekly financial market commentary. He is a philosopher, issuing insights on a wide range of subjects to over a million cohorts. An international audience of opinion makers, business leaders, and global organizations recognize Ebeling as an expert.